Swiss drugmaker Roche, whose multiple sclerosis (MS) drug Ocrevus is being targeted by a rival medicine from Novartis, is advancing an experimental drug in a trial while also testing if Ocrevus works in a higher dose.
ZURICH: Swiss drugmaker Roche, whose multiple sclerosis (MS) drug Ocrevus is being targeted by a rival medicine from Novartis, is advancing an experimental drug in a trial while also testing if Ocrevus works in a higher dose.
Roche has started a late-stage clinical trial for its molecule fenebrutinib and is doing a clinical trial of higher-dose Ocrevus against relapsing MS and primary progressive MS. The company is also looking at Ocrevus for minority populations, it said in a statement on Wednesday.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Comments
0 comment